TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Pfizer Inc(PFE)

Jul 19, 2004
A great name for a long-term holding. A more conservative guidance brought the stock down. Drug stocks tend to do best when interest rates are rising.
Photo of Norman LevineNorman LevineUnlock Rating
$32.11

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Track your Stocks in your Watch List
WEAK BUY

Pfizer Inc(PFE)

Jul 12, 2004
Like this sector. Good name. Growth potential is good.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$33.63

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 09, 2004
Likes the quality stocks, especially the health related ones.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$34.00

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 04, 2004
One of the world's best drug companies and as cheap as it's been in the long, long time.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$35.62

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

May 25, 2004
Large, US pharmaceutical stocks typically do well in a rising interest rate environment.
Photo of Neil WickhamNeil WickhamUnlock Rating
$34.74

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 14, 2004
Photo of Gene HensslerGene Henssler
Owned
Unlock Rating
$35.53

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 13, 2004
A lot of international sales. Have one of the strongest pipelines. A great core holding.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$35.40

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Apr 29, 2004
(Top Pick March 29/04. Up 2.5%.) Lots of upside potential.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.57

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 07, 2004
On his watch list. Have a very strong product offering. High quality management. Probably the best drug portfolio and retail pipeline.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$35.67

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2004
The inclusion in the DOW is significant and we'll give it an upward bias. One of the best pharmaceutical companies in the world. There is competition and drug pipelines are a little tougher. A little expensive.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$36.00

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Apr 01, 2004
Is going to be listed in the Dow on Monday which will have a positive impact for the short term. As a multiple in the low 20's. Has decent growth, but it's less than the multiple. Probably reasonably valued and any upside would make it overvalued.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$35.59

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Has reached about a 20-year valuation low. Relatively cheap.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Have a great lineup of existing drug products and lots more in the pipeline. At about 18 X earnings. Cheap.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 19, 2004
Thinks it's going to grow earnings at 15% this year.
Photo of Paul O'NeilPaul O'Neil
Owned
Unlock Rating
$33.95

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 09, 2004
(A top pick Dec 29/03. Up 7.2%.) Still likes. As far and away the best growth profile in pharmaceuticals. Growing the fastest even though it's the most expensive.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$37.30

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 736 to 750 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like